The aim of present study was to develop and submit antidiabetic bilayer tablet of sustain release Glimepiride and Immediate release Pioglitazone HCl. The drug procurement was completed from the gift sample from various companies. Sustained release of Glimepiride developed by using polymer like HPMC K4M and HPMC K100M. Super disintegrants such as Crospovidone and Kyron T-314 are used to prepare the immediate release layer. The drug excipient compatibility study was done with help of FTIR and there was no chemical interaction found in the study. The powder blend was evaluated for the various aspects such as the angle of repose, bulk density, tapped density, Hausner’s ratio, Carr’s index. The results were satisfied and showed the good result hence the conclusion that we can go for the tablet manufacturing. The tablets were manufactured with help of the direct compression method. The prepared tablets were evaluated for different tests and found in limit of uniformity of weight, hardness, thickness, diameter, and friability. Tablets from each batch studied for the drug content and was found within range of 96-99%, disintegration test was performed, the time was found 62-85sec. The In vitro dissolution was performed by using USP Type II apparatus. The release data further indicated that HPMC K100M can give the sustained release with maximum drug release up to 12 hrs. Which shows minimize the burden of dosing. Immediate Release layer IR6 containing Kyron T314 shows maximum drug release about 98.10 % up to 40 min. than other formulations. HPMC K100M polymer controlled the release of Glimepiride up to 12 hr. intended for once daily administration. The release data of In vitro study indicates that formulation follows zero order, Higuchi equation and diffusion takes place via non-fickian transport. The optimized tablets were studied for the stability study for period of 3 months. Formulation F3 found to be stable at accelerated stability as per the ICH guidelines for a period of 3 months.